References
- DeCardenas R, Helfrich J. Oral therapies and safety issues for oncology practices. Oncol Issues. 2010;(March/April): 40–42.
- Choi S, Boehnke L. Oral chemotherapy: A shifting paradigm affecting patient safety. Hem Onc Today. November 25, 2008. www.hemonctoday.com/article.aspx?rid=33070. Accessed April 28, 2011.
- Mancini R, Kaster M, Vu B, et al. Implementation of a pharmacist-managed interdisciplinary oral chemotherapy program in a community cancer center. J Hematol Oncol Pharm. 2011;1(2): 23–30.
- Hede K. Increase in oral cancer drugs raises thorny issues for oncology practice. J Natl Cancer Inst. 2009;101:1534–1536.
- Jacobsen JO, Polovich M, McNiff KK, et al. American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. Oncol Nurs Forum. 2009;36:651–658.
- Increased use of oral chemotherapy drugs spurs increased attention to patient compliance. J Oncol Pract. 2008;4:175–77.
- Weingart SN, Flug J, Brouillard D, et al. Oral chemotherapy safety practices at US cancer centers: Questionnaire survey. BMJ. 2007;334:407.
- Rand Corporation. A Review of Barriers to Medication Adherence: A Framework for Driving Policy Options. Santa Monica: CA; 2009.
- Moore S, Stoker Y. Promoting patient adherence to oral cancer treatment. Oncol Nurs Forum. 2008;35(3): 2728–9.
- Givens BA, Spoelstra S, Grant M. The challenges of oral agents as antineoplastic treatments. Semin Oncology Nurs. May 2011;27(2): 93–103.